EMEA-002889-PIP02-20-M01 - paediatric investigation plan
Ublituximab
PIPHuman
Key facts
- Invented name
- Briumvi
- Active Substance
- Ublituximab
- Therapeutic area
- Nervous system disorders
- Decision number
- P/0254/2024
- PIP number
- EMEA-002889-PIP02-20-M01
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of multiple sclerosis
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Neuraxpharm Pharmaceuticals S.L.
E-mail: nxregulatory@neuraxpharm.com
Tel.: +34 934759600- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date